Clinical trials: Enterocolitis, Pseudomembranous
Clostridium Enterocolitis, Pseudomembranous Colitis
Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis
The purpose of this study is to compare the outcome of treatment with nitazoxanide vs. vancomycin for diarrheal disease due to Clostridium difficile in patients who have failed previous treatment with metronidazole.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304889
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile, Clostridium Difficile Infection
FQ Restriction for the Prevention of CDI
This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs).
- Conditions
- Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis
- Trial name
- FIRST (NCT03848689)
- Testing
- fluoroquinolone preprescription authorization, Control
- Where
- 7 sites in United States
- Volunteers
- 5,871 people
- Sponsor
- University of Wisconsin, Madison
Clostridia Difficile Colitis, Clostridium Difficile Diarrhea
Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection
Fecal microbiota transplantation (FMT) is a treatment that restores the balance of gut bacteria and is the most effective treatment for patients who suffer from recurrent Clostridioides difficile infection (CDI) brought on by…
- Trial name
- NCT03806803
- Testing
- Lyophilized fecal microbiota transplant, Lyophilized sterile fecal filtrate
- Where
- 5 sites in Canada
- Volunteers
- 138 people
- Sponsor
- University of Alberta
Clostridium Difficile Colitis
Extended Treatment With Vancomycin for Clostridium Difficile Colitis
BACKGROUND: Clostridium difficile-associated colitis is an infection of the large bowel, usually associated with previous use of antibiotics.
- Trial name
- NCT00861887
- Testing
- Standard Vancomycin, Extended Vancomycin
- Where
- United States
- Sponsor
- Corewell Health East
Clostridium Difficile Colitis
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection
The incidence of C. difficile infection (CDI) has alarmingly increased over the past several years and the affected population has expanded to include those previously at low risk, such as children.
- Trial name
- NCT01972334
- Testing
- FMT
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- MemorialCare Health System
Crohn Disease, Ulcerative Colitis
Safety and Efficacy of Fecal Microbiota Transplantation
The gut microbiota is critical to health and functions with a level of complexity comparable to that of an organ system. Dysbiosis, or alterations of this gut microbiota ecology, have been implicated in a number of disease…
- Conditions
- Crohn Disease, Ulcerative Colitis, Celiac Disease, Irritable Bowel Syndrome
- Trial name
- NCT04014413
- Testing
- Fecal Microbiota Transplantation
- Where
- Hong Kong
- Volunteers
- 450 people
- Sponsor
- Chinese University of Hong Kong
Clostridium Enterocolitis, Pseudomembranous Colitis
Response of Clostridium Difficile Infection to Metronidazole Therapy
In this record review study, our objective is to determine the rates of cure, failure and relapse following treatment of C. difficile colitis with metronidazole.
- Conditions
- Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
- Trial name
- NCT00304369
- Testing
- Metronidazole
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile Infection, Diarrhea
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
This study will further evaluate the ACAM-CDIFF™ vaccine in a population of middle-aged to elderly individuals at risk of exposure to Clostridium difficile because of impending hospitalization or residence in a care facility.
- Trial name
- NCT01230957
- Testing
- Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant)
- Where
- 30 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection (CDI)
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
This is a prospective, multicenter, randomized, double-blinded, placebo-controlled Phase 3 study of a microbiota suspension of intestinal microbes.
- Trial name
- NCT03244644
- Testing
- RBX2660, Open label RBX2660 (only for confirmed CDI recurrence)
- Where
- 66 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- Rebiotix Inc.
Enterocolitis, Pseudomembranous Colitis
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
The purpose of this study is to determine whether dietary supplementation with Lactobacillus GG will reduce the rate of failure or relapse following treatment of CDAD with metronidazole.
- Conditions
- Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis
- Trial name
- NCT00304863
- Testing
- Lactobacillus GG
- Where
- United States
- Sponsor
- Michael E. DeBakey VA Medical Center
Clostridium Difficile Colitis
Phase I Trial of a Single Dose of CRS3123
Double-blind, randomized, placebo-controlled Phase I Trial to determine the safety and pharmokinetics of a single dose of CRS3123 in healthy adult volunteers.
- Trial name
- NCT01551004
- Testing
- CRS3123
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile, Enterocolitis, Pseudomembranous
Antimicrobial Stewardship Program for Clostridium Difficile Infection.
The purpose of this study is to determine whether a bundle of measures specifically designed for patients with ICD and applied by and Infectious Diseases expert during a year period (2017) will improve the prognosis and reduce…
- Trial name
- PACTA-ICD (NCT02951481)
- Testing
- Systematic evaluation by an ID expert.
- Where
- Spain
- Volunteers
- 403 people
- Sponsor
- José María Aguado García, MD, PhD
Clostridium Difficile Colitis
Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis
The investigators hypothesize that minimally invasive ileal diversion with intraoperative colonic lavage using a high volume polyethylene glycol/electrolyte solution will clear Clostridium difficile infection resulting in…
- Trial name
- NCT01441271
- Testing
- Ileal diversion and lavage, total abdominal colectomy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Massachusetts General Hospital
Gastrointestinal Hemorrhage, Clostridium Difficile Colitis
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.
study is to determine if proton pump inhibitors plus enteral nutrition is superior to enteral nutrition alone as a stress ulcer prophylaxis strategy in critically ill patients in terms of incidence of overt and significant GI…
- Trial name
- NCT01477320
- Testing
- Pantoprazole 40 mg IV daily and tube feed.
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Mohamed Saad
Clostridium Enterocolitis, Diarrhea
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea
Approximately 520 patients will be entered into this study taking place throughout Australia and Europe. This study aims to determine if an investigational drug is safe and effective for treating symptoms of C.
- Trial name
- NCT00196794
- Testing
- Tolevamer potassium-sodium (GT267-004)
- Where
- 138 sites in Australia, Austria and 12 more
- Volunteers
- 520 people
- Sponsor
- Genzyme, a Sanofi Company
Clostridium Difficile, Pseudomembranous Colitis
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection
Fecal microbiota transplantation (FMT) is acknowledged as a highly effective treatment for recurrent Clostridium difficile infection (CDI). Usually single fecal infusion achieves satisfactory cure rates of recurrent CDI).
- Trial name
- NCT03427229
- Testing
- Single-infusion FMT, Vancomycin (before randomization), multiple-infusion FMT
- Volunteers
- 58 people
- Sponsor
- Catholic University of the Sacred Heart
Clostridium Enterocolitis, Pseudomembranous Colitis
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection
The purpose of this study is for compassionate use of nitazoxanide in the treatment of diarrheal disease due to Clostridium difficile infection when the patient has failed previous treatment with metronidazole or vancomycin.
- Trial name
- NCT00304356
- Testing
- Nitazoxanide
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Daniel M. Musher MD
Clostridium Difficile Infection
Safety and Clinical Effectiveness of Oral Probiotic MIYA-BM to Prevent Recurrent Clostridium Difficile Infections
Patients with confirmed C. difficile infection (CDI) who meet eligibility requirements will be invited to participate. All study patients must receive treatment for CDI with metronidazole or vancomycin.
- Trial name
- NCT01077245
- Testing
- MIYA-BM Fine Granules (CBM588)
- Sponsor
- Osel, Inc.
Clostridia Difficile Colitis
Vancomycin Taper to Prevent Recurrent Clostridioides Difficile
Indirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides…
- Trial name
- TAPER-V2 (NCT07328971)
- Testing
- Fidaxomicin, Vancomycin capsule
- Where
- 2 sites in Canada
- Volunteers
- 500 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Clostridioides Difficile Infection, Clostridium Difficile Infection
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident…
- Conditions
- Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
- Trial name
- ACT (NCT04305769)
- Testing
- Alanyl-glutamine
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- University of Virginia